Pfizer still first with doctors
For the sixth consecutive year, New York-based Pfizer Inc.'s pharmaceutical sales organization placed first overall in Newtown, PA-based healthcare consulting firm Scott-Levin's survey of U.S. physicians in nine core specialty groups: general/family practitioners, internists, pediatricians, obstetrician/gynecologists, psychiatrists, general surgeons, gastroenterologists, cardiologists and otorhinolaryngologists.
For the sixth consecutive year, New York-based Pfizer Inc.'s pharmaceutical sales organization placed first overall in Newtown, PA-based healthcare consulting firm Scott-Levin's survey of U.S. physicians in nine core specialty groups: general/family practitioners, internists, pediatricians, obstetrician/gynecologists, psychiatrists, general surgeons, gastroenterologists, cardiologists and otorhinolaryngologists.
Pfizer was rated first by five of these key physician groups, as well as urologists, nephrologists, emergency medicine specialists and neurosurgeons. The company also was ranked number one by nurse practitioners and physician assistants.
The report also examined sales force value among physician specialty groups. The leading sales forces among select groups of specialists:
•Â Allergists: Aventis Pharmaceuticals, Parsippany, NJ.
•Â OB/GYNs: Wyeth-Ayerst Laboratories, Philadelphia, PA.
•Â Oncologists: Bristol-Myers Squibb Co., New York.
•Â Orthopedic surgeons: Merck & Co. Inc., Whitehouse Station, NJ.
•Â Psychiatrists: Eli Lilly and Co., Indianapolis.
These rankings come from "Pharmaceutical Sales Force Structures & Strategies 2000-2001," the 13th edition of Scott-Levin's annual study of pharmaceutical sales forces. Thirty-three physician specialty groups and other healthcare providers were surveyed for this year's report. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
